Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Historical or Hysterical Info
View:
Post by Red~One on Apr 07, 2022 8:13pm

Historical or Hysterical Info

Regarding the latest NR in respect to the mention of the Barda Grant ..........................On May 19, 2020, Kalytera announced that it had signed a Letter of Intent dated May 12, 2020 (the “LOI”) to acquire Salzman Group. At that time, a valuable asset of Salzman Group was its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. Under this contract, BARDA awarded Salzman Group USD $15.9 million to develop R-107 as a treatment for chlorine inhalation lung injury (“CILI”). An additional USD $69.9 million could have been released to Salzman Group over the next 36 months, as developmental milestones were achieved. Under GAAP, these U.S. government funds would have been recognized as contract revenues when received over that period, and it was anticipated that Salzman Group would recognize net operating profits of approximately USD $1.4 million per year from these contract revenues. However, on September 16, 2020, Salzman Group was informed that BARDA was terminating the BARDA Contract and diverting its funding under the BARDA Contract, and all similar contracts, to support projects for prevention of COVID-19 infection. The Company was not informed directly of this from BARDA, but learned about this afterward from Salzman Group.
Comment by Whyme16 on Apr 08, 2022 8:50am
Red~One, Very true. This is ONE EXAMPLE of how BOB the PUPPET deceived investors to facilitate SALZMAN steal our investment.......There have been COUNTLESS number of TRICKS played by BOB the PUPPET over the last few years........But I trusted him after this stock got back on the trading patform in 2021 NOT REALIZING that this was also part of the plan by SALZMAN to ROB us from what was left from ...more  
Comment by Canary001 on Apr 08, 2022 9:26am
Can you tell me why you think that was a sham? I bought right after that PR.
Comment by Whyme16 on Apr 08, 2022 10:00am
Just look at the BARDA announcement. That's one example...on the surface it seems a golden opportunity but then cancelled! SALZMAN did the very samething at RS time...they said all ducks are in row EXECPT that we need a higher SP so that some of the instituions could invest AND they were the FIRST one to off-load shares dragging the SP from 47 cents to 10 cents!! Then there was that whole f. ...more  
Comment by Canary001 on Apr 08, 2022 10:46am
Well I agree with the chronology you lay out but I don't see fraud or deception here. I see a hopelessly undercapitalized company that has been propped up by Salzman. The shareholders sure haven't done well but Salzman is the big loser in all of this. Claritas hasn't moved his technology forward an inch so he's lost the potential to make millions after he invested millions of his ...more  
Comment by Whyme16 on Apr 08, 2022 11:08am
I doubt you are a real investor willing to lose money.........just keep in mind that the PHASE ONE start date has not moved the gauge AND that's telling us all something.........THIS COMPANY BACKED BY SALZMAN HAS NO CREDIBILITY WHATSOEVER..........Salzman already robbed us from GVHD! WE PAID FOR IT AND NOW THEY OWN IT!!!!!!!! Go figure....... I don't understand how you don't see the ...more  
Comment by Canary001 on Apr 08, 2022 11:16am
The GVHD program was given to Talent Biotech, not Salzman. I do my homework befor I invest. If you hate the company, PLEASE sell as fast and as much as you can. I would love to average down. PLEASE SELL!
Comment by Red~One on Apr 08, 2022 11:36am
The GHVD program and research was not "GIVEN" to Talent , it was a payment for money/security owed. That is CLAS' modus operandi....why use cash if you can defer it to shares?
Comment by Canary001 on Apr 08, 2022 12:39pm
Talent owned the GVHD technology. Claritas acquired Talent in order to get the GVHD technology. When Claritas couldn't monetize the technology via an out-license to a strategic partner it decided to give back Talent to its original shareholders. This is all in the public docs from Claritas. DO YOUR HOMEWORK! And in the meantime please sell sell sell so I can get more shares on the cheap. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities